BridgeBio Pharma’s BBP‑418 for LGMD2I/R9 accepted by FDA with Priority Review; PDUFA date set for November 27, 2026, marking potential first therapy for limb‑girdle muscular dystrophy.
Written By: Mahathi Palivela, PharmD
Reviewed By: Pharmacally Editorial Team
BridgeBio Pharma secured a major regulatory milestone after the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) and granted Priority Review. The agency assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026, and indicated it does not currently plan to convene an advisory committee meeting.
First-in-Class Potential
If approved, BBP-418 would become the first therapy for LGMD2I/R9 and potentially the first authorized treatment for any form of limb-girdle muscular dystrophy. BridgeBio stated it is preparing for a commercial launch immediately following potential approval.
Clinical Evidence
The NDA is supported by data from the Phase 3 FORTIFY trial (NCT05775848). At the pre-specified 12-month interim analysis, BBP-418 met all primary and secondary endpoints. Treated patients improved across all major functional endpoints, while placebo recipients continued to decline in line with the natural progression of the disease.
The results were presented during a late-breaking session at the 2026 MDA Clinical and Scientific Conference.
Mechanism of Action
BBP-418 is an investigational oral glycosylation substrate therapy that enhances residual FKRP enzyme activity by increasing substrate availability. The therapy aims to restore alpha-dystroglycan glycosylation and stabilize muscle function across ambulatory, respiratory, and cardiac domains.
Stakeholder Perspectives
Christine Siu, Chief Executive Officer of BridgeBio Neuromuscular, said the FDA decision advances the company toward potentially changing the course of LGMD2I/R9 for patients who currently lack approved treatment options.
Patient advocacy leaders also described the regulatory milestone as an important step forward for families living with the disease.
Designations and Global Strategy
BBP-418 has received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations, along with Orphan Drug designation from the European Medicines Agency.
BridgeBio is also pursuing an expedited regulatory pathway in Europe and plans to initiate additional studies in younger LGMD2I/R9 patients as well as other FKRP-related muscular dystrophy subtypes. Additional planned studies could expand BBP-418 into broader muscular dystrophy populations.
Disease Background
LGMD2I/R9 is a rare inherited neuromuscular disorder caused by mutations in the FKRP gene, which impair glycosylation of alpha-dystroglycan, a protein essential for muscle stability. The disease progressively weakens skeletal, respiratory, and cardiac muscles, often leading to loss of ambulation, cardiomyopathy, respiratory failure, and shortened survival.
Approximately 7,000 individuals in the United States and Europe are estimated to live with LGMD2I/R9 and related α-dystroglycanopathies.
Reference
BridgeBio-Announces-FDA-Acceptance-and-Priority-Review-of-NDA-for-BBP-418-for-LGMD2IR9-2026.pdf
About the Writer
Mahathi Palivela (LinkedIn) is pursuing PharmD and has a strong interest in Clinical Pharmacy and Patient safety. She is passionate about handling and analyzing patient data, and translating clinical insights into clear, meaningful summaries. She aims to apply this interest in Medical Writing and Pharmacovigilance, focusing on improving patient outcomes through careful data interpretation and communication.